Straits Times Index
3,342.05 +12.04 (+0.36%) Nikkei
38,797.67 +307.50 (+0.80%) Hang Seng
18,473.66 +48.70 (+0.26%) FTSE 100
8,246.95 +14.91 (+0.18%) Bitcoin USD
70,907.93 -53.64 (-0.08%) CMC Crypto 200
1,520.28 +46.54 (+3.16%)
OCGN Jun 2024 0.500 put
| Previous close | 0.0500 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 0.50 |
| Expiry date | 2024-06-21 |
| Day's range | 0.0500 - 0.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksOcugen (OCGN) Skyrockets 209.6% Year to Date: Heres Why
Ocugen's (OCGN) shares rise significantly in the year-to-date period on positive progress with its promising pipeline candidates.
GlobeNewswireData and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy
Established Medium Dose as Safe and Tolerable Dose in Current OCU410 Clinical TrialDSMB Recommends Continuing with High-Dose Cohort Dosing with Concurrent Phase 2 Dosing MALVERN, Pa., May 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced a positive outcome of the Data and Safety Monitoring Board (DSMB) Review for its Phase 1/2
- GlobeNewswire
Ocugen to Present at BIO International Convention 2024
MALVERN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company will present at the 2024 BIO International Convention taking place in San Diego, CA from June 3 – 6, 2024. During the conference, Ocugen’s leadership team will host meetings with potential partners and pharmaceutical executives to explore oppo
